Three OCN-501 Preclinical Studies to Be Presented at International Conference
Expanding Development as an Independent Treatment for Muscle Disorders

Onconic Therapeutics is expanding the development of its next-generation muscle metabolism drug OCN-501 beyond its use in combination with incretin-based obesity treatments, such as glucagon-like peptide-1 (GLP-1) drugs, to preserve muscle, targeting muscle-wasting diseases such as cachexia.


Onconic Therapeutics announced on November 19 that three preclinical studies of OCN-501 for cachexia had been selected for poster presentations at the 19th International Conference on Cachexia, Sarcopenia and Muscle Wasting, SCWD 2026, to be held in Washington, D.C., from December 10 to 12 (local time).


A view of the Onconic Therapeutics research center. Onconic Therapeutics

A view of the Onconic Therapeutics research center. Onconic Therapeutics

View original image

OCN-501 is an oral small-molecule drug under development to maintain energy metabolism homeostasis in muscle and alleviate signals that trigger protein breakdown. At ObesityWeek 2026, the company presented preclinical findings showing that, when used in combination with semaglutide, OCN-501 maintained weight-loss effects while significantly improving muscle mass-related indicators and significantly suppressing declines in grip strength, a measure of actual muscle function. Fat tissue also decreased further.


The company said that the selection of three additional cachexia studies for SCWD 2026 expands the potential for OCN-501 to be developed as an independent treatment for muscle metabolism disorders, beyond its use in combination with obesity treatments. Detailed methods and results of the cachexia studies will be presented at the conference.



An Onconic Therapeutics official said, "The core value of OCN-501 is that it is a new drug targeting both muscle mass and function, and that it can be developed for a range of muscle disorders, including in combination with obesity treatments. We aim to improve the quality of weight loss in the obesity treatment field and develop an independent treatment for cachexia."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing